EGFR mutations and EGFR TKI treatment had relevance with the increased PD-L1 levels, which suggests the combination of anti-PD-1/PD-K1 with TKIs may be synergistically effective to NSCLC (D’Incecco et al., 2015). Here, EGFR is linked to non-small cell lung carcinoma.